Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (747)	10/6/2005 12:51:26 PM
From: tuck	Read Replies (1) of 897

Thanks to Steve (quidditch) for this dig from Goldman Sachs regarding Trimeris: >>Trimeris (TRMS, In-Line). Keep estimates but note Fuzeon pickup Americas Healthcare: Biotechnology October 6, 2005 Goldman Sachs Global Investment Research 4 Script trends for Fuzeon have been on a steady uprise, even through the late summer which has historically been seasonally week. We maintain our forecast of $26 million in North American sales and $26 million in Ex-U.S. sales. The sequential number is down from Q2 ex-U.S., due to one time shipments to Brazil. We are forecasting a Q3 loss of ($0.16) per share and full year 2005 loss of ($0.61). Each of the analysts named below hereby certifies...[snip]<< I actually did have a little short position on Trimeris, which I took small profits on at about these levels a couple of days ago. Trimeris would suffer on an earnings miss, IMO. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next